Trial Profile
A Two-arm, Placebo-controlled Randomized Clinical Trial to Evaluate the Effect of Dupilumab on Airway Hyper-responsiveness and Ventilation Heterogeneity in Patients With Asthma With a "T2 Immune Signature"
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 18 Jan 2023 Status changed from recruiting to completed.
- 06 Sep 2021 Planned End Date changed from 1 Jun 2021 to 1 Jun 2022.
- 06 Sep 2021 Planned primary completion date changed from 1 Apr 2021 to 1 Apr 2022.